NCT06237205View on ClinicalTrials.gov

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Efficacy
Interventions
DRUG

Niraparib

a highly selective PARP1 and PARP2 inhibitor

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

Korean Cancer Study Group

OTHER

lead

Korea University Anam Hospital

OTHER